4//SEC Filing
Howe Jolanda 4
Accession 0001415889-25-008558
CIK 0001759425other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 9:30 PM ET
Size
18.3 KB
Accession
0001415889-25-008558
Insider Transaction Report
Form 4
Howe Jolanda
SVP, GLOBAL CONTROLLER
Transactions
- Exercise/Conversion
Performance Restricted Stock Units
2025-03-15−5,315→ 2,658 total→ Common Stock (5,315 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-03-17−52,900→ 0 totalExercise: $2.94Exp: 2029-03-11→ Common Stock (52,900 underlying) - Exercise/Conversion
Common Stock
2025-03-15+5,315→ 9,547 total - Exercise/Conversion
Common Stock
2025-03-17$2.94/sh+52,900$155,526→ 59,547 total - Sale
Common Stock
2025-03-17$44.33/sh−50,111$2,221,626→ 9,436 total - Sale
Common Stock
2025-03-17$44.75/sh−2,789$124,802→ 6,647 total - Sale
Common Stock
2025-03-17$44.36/sh−1,806$80,113→ 4,841 total - Sale
Common Stock
2025-03-17$44.21/sh−2,900$128,221→ 6,647 total
Footnotes (8)
- [F1]Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
- [F3]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 16, 2024.
- [F4]The weighted average sale price for the transaction reported was $44.33410, and the range of prices were between $43.695 and $44.695. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $44.74811, and the range of prices were between $44.70 and $44.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F6]The weighted average sale price for the transaction reported was $44.35923, and the range of prices were between $43.81 and $44.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F7]The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.
- [F8]The stock option is fully vested.
Documents
Issuer
Mirum Pharmaceuticals, Inc.
CIK 0001759425
Entity typeother
Related Parties
1- filerCIK 0001974200
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 9:30 PM ET
- Size
- 18.3 KB